Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.
Potential reduced exposure products (PREPs) are being developed and marketed by the tobacco
industry in an attempt to reduce some of the risks involved in tobacco use (see Breland et
al., 2002b). Evaluating the effects of these products is crucial to public health, as past
industry-sponsored efforts at harm reduction (e.g., so-called "light" and "ultra-light"
cigarettes) were not evaluated and failed to reduce carbon monoxide (CO), nicotine, and
carcinogen exposure in smokers; these efforts thus failed to reduce the harms of smoking
(Stratton et al., 2001). This study is part of an on-going, NIH-funded program of research
to develop a science-based model that uses outcome measures relevant to evaluating current
tobacco industry-sponsored smoking harm reduction efforts systematically and efficiently.
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Plasma nicotine concentration (ng/ml)
baseline, 5, 15, 30, and 45 minutes post-use
Thomas Eissenberg, Ph.D.
Virginia Commonwealth University
United States: Federal Government
|Clinical Behavioral Pharmacology Laboratory||Richmond, Virginia 23298|